A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

TitleA phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Publication TypeJournal Article
Year of Publication2013
AuthorsKelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, Poondru S, Van Sant C, Keating A, Steinberg SM, Figg W, Giaccone G
JournalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume24
Issue10
Pagination2601-6
Date Published2013 Oct
Abstract

This phase I/II study examined the safety and efficacy of Sepantronium Bromide (S), a small-molecule selective survivin suppressant, administered in combination with carboplatin (C) and paclitaxel (P).

DOI10.1088/0957-4484/24/31/315203
Alternate JournalAnn. Oncol.